We are live on
!
Find out more
Squarepoint Portfolio holdings
AUM
$85.1B
1-Year Est. Return
20.93%
This Fund
S&P 500
This Quarter
Est. Return
+4.45%
1 Year Est. Return
+20.93%
3 Year Est. Return
+51.38%
5 Year Est. Return
+34.63%
10 Year Est. Return
+146.23%
AUM
$24.5B
AUM Growth
-$766M
(-3%)
Cap. Flow
+$1.16B
Cap. Flow
% of AUM
4.71%
Top 10 Holdings %
Top 10 Hldgs %
14.99%
Holding
4,039
New
907
Increased
1,143
Reduced
1,068
Closed
874
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$208M |
| 2 |
CVS Health
CVS
|
+$132M |
| 3 |
Comcast
CMCSA
|
+$114M |
| 4 |
Honeywell
HON
|
+$94.8M |
| 5 |
ConocoPhillips
COP
|
+$92.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street Materials Select Sector SPDR ETF
XLB
|
+$233M |
| 2 |
iShares China Large-Cap ETF
FXI
|
+$228M |
| 3 |
Apple
AAPL
|
+$195M |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$157M |
| 5 |
Nike
NKE
|
+$132M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 10.7% |
| 2 | Consumer Discretionary | 10.58% |
| 3 | Healthcare | 6.83% |
| 4 | Industrials | 5.75% |
| 5 | Financials | 5.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3001
INmune Bio
INMB
$43.1M
| $84.3K | ﹤0.01% |
+13,045
| New | +$105K |
|
3002
ARS Pharmaceuticals
SPRY
$590M
| $84K | ﹤0.01% |
+12,903
| New | +$99.1K |
|
|
SRTA
3003
Strata Critical Medical Inc
SRTA
$436M
| $83.9K | ﹤0.01% |
+24,819
| New | +$101K |
|
3004
Genworth Financial
GNW
$3.8B
| $83.6K | ﹤0.01% |
16,663
-13,486
| -45% | -$74.7K |
|
3005
Olema Pharmaceuticals
OLMA
$1.02B
| $83.1K | ﹤0.01% |
+23,943
| New | +$97.7K |
|
3006
American Superconductor
AMSC
$1.48B
| $82.6K | ﹤0.01% |
+16,818
| New | +$84.5K |
|
|
BHIL
3007
DELISTED
Benson Hill, Inc.
BHIL
| $82.3K | ﹤0.01% |
2,046
+1,624
| +385% | +$121K |
|
|
CAMP
3008
DELISTED
CalAmp Corp.
CAMP
| $82.2K | ﹤0.01% |
+996
| New | +$97.3K |
|
3009
Wave Life Sciences
WVE
$1.12B
| $82.1K | ﹤0.01% |
+18,972
| New | +$86.9K |
|
|
PTVE
3010
DELISTED
Pactiv Evergreen Inc. Common stock
PTVE
| $82K | ﹤0.01% |
+10,247
| New | +$105K |
|
3011
Newegg Commerce
NEGG
$296M
| $81.6K | ﹤0.01% |
+3,045
| New | +$95K |
|
3012
Ponce Financial Group
PDLB
$489M
| $80.7K | ﹤0.01% |
+10,276
| New | +$93.1K |
|
|
HAPN
3013
Happen Inc
HAPN
$2.08B
| $78.6K | ﹤0.01% |
10,904
-5,700
| -34% | -$50.8K |
|
3014
System1
SST
$15M
| $78.6K | ﹤0.01% |
+1,827
| New | +$81K |
|
3015
Acumen Pharmaceuticals
ABOS
$154M
| $78.5K | ﹤0.01% |
+19,343
| New | +$101K |
|
3016
Atea Pharmaceuticals
AVIR
$379M
| $76.3K | ﹤0.01% |
22,777
-16,237
| -42% | -$65.9K |
|
|
INN
3017
Summit Hotel Properties
INN
$761M
| $74.2K | ﹤0.01% |
+10,605
| New | +$80.4K |
|
3018
Quantum Corp
QMCO
$437M
| $73.9K | ﹤0.01% |
+3,214
| New | +$83.9K |
|
3019
CytomX Therapeutics
CTMX
$705M
| $73.8K | ﹤0.01% |
+48,856
| New | +$110K |
|
|
GTHX
3020
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $73.6K | ﹤0.01% |
27,455
-21,859
| -44% | -$105K |
|
3021
Cue Biopharma
CUE
$135M
| $72.2K | ﹤0.01% |
+674
| New | +$64.3K |
|
3022
Outlook Therapeutics
OTLK
$263M
| $71K | ﹤0.01% |
+3,257
| New | +$72.9K |
|
3023
Freightos
CRGO
$65.1M
| $70.5K | ﹤0.01% |
+20,443
| New | +$107K |
|
3024
PLAYSTUDIOS Inc
MYPS
$79.3M
| $69.9K | ﹤0.01% |
18,934
-19,514
| -51% | -$79K |
|
|
KRON
3025
DELISTED
Kronos Bio
KRON
| $67.3K | ﹤0.01% |
46,088
+15,870
| +53% | +$30.4K |
|
Similar funds
Squarepoint's Q1 2023 Portfolio in Review
As of Q1 2023, Squarepoint held 4,039 positions worth $24.5B, down 3% from $25.3B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Squarepoint deployed $1.16B of net new capital in Q1 2023, opening 907 new positions and adding to 1,143 existing holdings. Its largest new stake was iShares iBoxx $ High Yield Corporate Bond ETF: 2,782,957 shares worth $210M.
By sector, the portfolio is most concentrated in Technology at 11% of assets, up from 10% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was State Street Materials Select Sector SPDR ETF, an estimated $233M trimmed.
- Squarepoint's largest Q1 2023 buy was iShares iBoxx $ High Yield Corporate Bond ETF: 2,782,957 shares worth $210M.
- Squarepoint added most to CVS Health in Q1 2023, an estimated $132M increase.
- Squarepoint's biggest Q1 2023 reduction was State Street Materials Select Sector SPDR ETF, cutting an estimated $233M.
- Squarepoint fully exited Mondelez International in Q1 2023, selling an estimated $95.9M.
- Squarepoint's ten largest holdings make up 15% of its $24.5B portfolio in Q1 2023.
- Squarepoint opened 907 new positions and closed 874 in Q1 2023.
- Squarepoint's portfolio value fell 3% quarter-over-quarter to $24.5B.
Based on Squarepoint's 13F filing for Q1 2023, filed 15 May 2023.